Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06212479 · ClinicalTrials.gov registry record

An Observational Study On TheAccuracy Of Whole-Body Magnetic Resonance Imaging (Wb-Mri) ScreeningTo Predict Clinically Significant Diagnoses In General Population Subjects Interested In Proactive And Advanced General Preventive Healthcare.

A clinical trial of Cancer and Metabolic Disease, sponsored by Hercules.

Recruiting
Registry status
100,000
Enrollment target
1
Study location

NCT06212479: Recruiting study of Cancer and Metabolic Disease, sponsored by Hercules.

NCT06212479 is a study of Cancer and Metabolic Disease that is actively recruiting participants, run by Hercules. The registered enrollment target is 100,000 participants, above the 3,329-participant average among 615 other Cancer trials with a reported enrollment target (2904% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT06212479, a study of Cancer and Metabolic Disease, is actively recruiting participants, sponsored by Hercules.

RECRUITING
Registry status
100,000 participants
Enrollment target
1
Study location

Study Summary

This is a prospective, single-arm, observational study capturing data from whole-body magnetic resonance imagining (WB-MRI) from up to 100,000 male and female subjects 18 years of age or older recruited at multiple clinical sites within the United States. Study subjects must meet a set of inclusion and exclusion criteria. Potential subjects arriving at the study sites will be evaluated for enrollment. It is the Principal Investigator's (PI) responsibility to enroll only subjects who satisfy the inclusion/exclusion criteria. Recruitment can occur by subject presentation at the sites for elective standard screening, word-of-mouth, flyers, healthcare professional (HCP) referrals, advertisement online, or any other means, subject to approval by the associated institutional review board (IRB) or ethics committee (EC) when applicable.

Primary Outcome

Clinically significant disease represents the primary output of WB-MRI image analysis, and thus, the primary endpoint for this study. This outcome will be expressed as a 5-point scale similar to the standard Likert scale used in clinical studies. Higher the number higher the risk of clinically significant finding.

Interventions

  • DIAGNOSTIC_TEST MRI Scan

Study Locations (1)

Massachusetts

  • Hercules Research Center - Watertown

Trial Details

FieldValue
Enrollment Target 100,000 participants
Start Date 2024-05-17
Est. Completion 2037-01
Hercules

1 total trials

What NCT06212479 shows while recruiting

NCT06212479 is an observational study that tracks outcomes without assigning an intervention. Its 100,000 participants enrollment target places it among the larger protocols in the corpus, above the 3,329-participant average among 615 other Cancer trials with a reported enrollment target (2904% higher).

The record links to 4 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which MRI Scan is the first listed.

NCT06212479 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06212479 about?

NCT06212479 is a clinical study titled "An Observational Study On TheAccuracy Of Whole-Body Magnetic Resonance Imaging (Wb-Mri) ScreeningTo Predict Clinically Significant Diagnoses In General Population Subjects Interested In Proactive And Advanced General Preventive Healthcare.". This is a prospective, single-arm, observational study capturing data from whole-body magnetic resonance imagining (WB-MRI) from up to 100,000 male and female subjects 18 years of age or older recruited at multiple clinical sites within the United States. Study subjects must meet a set of inclusion ...

What is the current status of trial NCT06212479?

This trial is currently recruiting. The enrollment target is 100,000 participants. The study started on 2024-05-17. Estimated completion is 2037-01.

What conditions does trial NCT06212479 study?

This clinical trial studies the following conditions: Cancer, Metabolic Disease, Neurologic Disorder, Aneurysm.

What interventions are being tested in trial NCT06212479?

The interventions under investigation include: MRI Scan (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT06212479?

This trial is sponsored by Hercules, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06212479 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06212479's enrollment target sits among peer trials

100,000 5th of 615 higher than 609 of 615 other Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02620852 · 100,000 participants · NA

    Women Informed to Screen Depending on Measures of Risk (Wisdom Study)

  • NCT03277365 · 100,000 participants · NA

    MyGeneRank: A Digital Platform for Next-Generation Genetic Studies

  • NCT04281823 · 100,000 participants

    DeBakey Cardiovascular Magnetic Resonance Study

  • NCT04869111 · 100,000 participants · NA

    The BrainHealth Project

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06212479, the US trial registry maintained by the National Library of Medicine. NCT06212479 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.